TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03533140

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DUCEST Neurostimulator V Group A
Description: The DUCEST Neurostimulator V needle-electrodes are applied post-operatively to stimulate the R.auricularis of the vagus nerve located at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates the device. (The stimulation intensity can be adjusted from 0,05mA to 1,2mA, default value is 0,4mA). The starting stimulation intensity will be adjusted to 1mA and takes place at 1Hz continuously for 40 minutes, followed by a 20 minute break. The built-in 3V battery lasts for approx. 14 days. After 7 days the electrodes are replaced and applied to the other ear of the patient. A plaster with a plastic mounting clip is attached on the shoulder of the patient. The Neurostimulator is connected to the mounting clip. After 14 days or at hospital discharge of the patient, the device is unmounted and the needle-electrodes are removed.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DUCEST Neurostimulator V Group B
Description: The DUCEST Neurostimulator V needle-electrodes are applied post-operatively at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates only the signal lamp but not the device.
Study: NCT03614169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of a HIS-pacing lead
Description: This intervention is attempted first
Study: NCT02891603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus (TAC) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of TAC taper. TAC levels will be monitored according to program standard operating procedures. Dose modifications of TAC for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogenic hematopoietic cell transplant (alloHCT)
Description: Patients will undergo allogenic hematopoietic cell transplant (alloHCT) as a part of their standard of care treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogenic hematopoietic cell transplant (alloHCT)
Description: Patients will undergo allogenic hematopoietic cell transplant (alloHCT) as a part of their standard of care treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogenic hematopoietic cell transplant (alloHCT)
Description: Patients will undergo allogenic hematopoietic cell transplant (alloHCT) as a part of their standard of care treatment.
Study: NCT03614169

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of a LV-pacing lead
Description: This intervention is attempted first
Study: NCT01591226

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: gelatine capsule 6mg/kg bodyweight 60min prior test

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: gelatine capsule 6mg/kg bodyweight 60min prior test

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Citrate
Description: 0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Citrate
Description: 0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride
Description: sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
Study: NCT02545062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MoCa test
Description: The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.
Study: NCT01591226

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
Study: NCT03086317

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Catheter-Directed Thrombolysis
Description: Catheter-directed thrombolysis requires placement of a multi-sidehole infusion catheter within the pulmonary arterial thrombus burden, under angiographic guidance. Thrombolytic medications are slowly infused through the catheter, which is left in place for the duration of the treatment. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-Accelerated Thrombolysis
Description: USAT is a modification of standard catheter-directed thrombolysis utilizing a proprietary system of local high frequency, low-power ultrasound to dissociate the fibrin matrix of the thrombus, allowing deeper penetration of lytic medication. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
Study: NCT04450732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GQ1001
Description: anti-HER2 antibody drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GQ1001
Description: anti-HER2 antibody drug conjugate
Study: NCT02808312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablet(s) administered orally in a fed state on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablet(s) administered orally in a fed state on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablet(s) administered orally in a fed state on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablet(s) administered orally in a fed state on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablet(s) administered orally in a fed state on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablet(s) administered orally in a fed state on Day 1
Study: NCT04949906

Intervention type: DRUG
Intervention: Raise serum brain granules
Description: Should Yangseronao granules be used in patients undergoing intravenous thrombolysis for the diagnosis of acute ischemic stroke
Study: NCT02444754

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Obtain medical data

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete demographics questionnaires

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study: NCT03038620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
Study: NCT04949906

Intervention type: DRUG
Intervention: No nourishing serum brain granules are used
Description: No nourishing serum brain granules are used
Study: NCT03038620

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
Study: NCT03808571

Intervention type: OTHER
Intervention: cord blood specimen during the delivery
Description: The cord blood will be taken during the delivery of baby.

Intervention type: OTHER
Intervention: cord blood specimen during the delivery
Description: The cord blood will be taken during the delivery of baby.
Study: NCT03035630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10mg/kg IV over 60 minutes on D1 and D15 of every 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10mg/kg IV over 60 minutes on D1 and D15 of every 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 50 mg once daily from D1 to D14 of every 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 50 mg once daily from D1 to D14 of every 21 day cycle
Study: NCT04136171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplontersen
Description: Eplontersen by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eplontersen-matching placebo by subcutaneous injection
Study: NCT00049543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02296125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 80 mg/40 mg + placebo
Description: The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Erlotinib 150/100mg
Description: The initial dose of Placebo Erlotinib 150 mg once daily can be reduced to Placebo 100 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gefitinib 250 mg
Description: The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib 150/100 mg
Description: The initial dose of Erlotinib 150mg once daily can be reduced to 10 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib 250 mg
Description: The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo AZD9291 80 mg/ 40 mg
Description: The initial dose of Placebo AZD9291 80 mg once daily can be reduced to Placebo AZD9291 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT01923922

Intervention type: RADIATION
Group type: OTHER
Intervention: CT Perfusion
Description: The CT perfusion scan will be performed on a multi-detector CT scanner at the time of routine preoperative neuronavigation imaging. A non-contrast CT head scan will be acquired to localize the tumour. Four 5 mm thick slices will be selected at the level of the tumour. Multiple images will be acquired at each levels starting 5 sec after the injection of 50 cc of non-ionic iodinated contrast media at a rate of 4 cc/sec. The acquisition parameters will be 80 kVp and 100 mA. The images will be acquired every second for a total of 110 sec. The post- processing will be performed and parameters will be calculated using regions of interest in the areas of tumour showing the highest perfusion values. Another region of interest will be placed in the contralateral normal looking white matter.
Study: NCT01481610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumiracoxib
Description: Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day), for a period no longer than 10 days, but no shorter than 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
Study: NCT02106832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (BAYQ3939) dry powder for inhalation
Description: Ciprofloxacin dry powder for inhalation (DPI) 32.5 mg inhaled twice daily in cycles of 28 days on-treatment and 28 days off-treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (BAYQ3939) dry powder for inhalation
Description: Ciprofloxacin DPI 32.5 mg inhaled twice daily in cycles of 14 days on-treatment and 14 days off-treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo inhaled twice daily intermittently for 28 days on / 28 days off

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo inhaled twice daily intermittently for 14 days on / 14 days off
Study: NCT01907893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Collaborative Care Plus Treatment as Usual
Study: NCT01490268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil, Hydromorphone
Description: Intraoperatively: Target controlled infusion with 0.4 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil, Hydromorphone
Description: Intraoperatively: Target controlled infusion with 0.8 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
Study: NCT02935218

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parenting Skills for Mothers with BPD
Description: The cognitive-behavioral Group Training for mothers with BPD consists of 12 weekly sessions promoting parenting skills including primary needs of children, stress and stress management, dealing with conflicts, mindfulness, emotion regulation, routine and flexibility, the role of the body in parenting, basic assumptions about parenting, and self-care.
Study: NCT02362685

Intervention type: DEVICE
Intervention: functional test
Description: subjects perform a metabolic exercise testing
Study: NCT03564171

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: stress counseling, exercise, nutritional counseling, smoking cessation counseling
Study: NCT02362685

Intervention type: GENETIC
Intervention: matching genotype with phenotype
Study: NCT02856581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tobacco Cessation Counseling
Description: Complete counseling session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Complete counseling session
Study: NCT01215734

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)
Description: 0.5 ml of HD-TIV on visit 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Trivalent Inactivated Flu Vaccine
Description: Twenty adult hematopoetic stem cell transplant recipients will receive 0.5 ml standard dose trivalent influenza vaccine on visit 1.
Study: NCT01065636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + Resistance Training
Description: Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and resistance exercise training 3-days/week for 24 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + Aerobic Training
Description: Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and aerobic exercise training 3-days/week for 24 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + Resistance/Aerobic Exercise
Description: Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and combined resistance/aerobic exercise training 3-days/week for 24 weeks
Study: NCT01912703

Intervention type: OTHER
Intervention: Telephone interview
Description: Subjects with incomplete data will be asked to complete a telephone interview
Study: NCT03583762

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mass spectrometry
Description: Molecular diagnostic test for bacterial identification from bacterial colony

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microarray assay
Description: Bacterial identification by Microarray assay from positive blood culture and confirmed by Mass spectrometry technique from bacterial colony. Adjusted antibiotic therapy according to AST Re-evaluation after treatment
Study: NCT04549597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Use of tenapanor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Use of tenapanor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Use of tenapanor
Study: NCT01343134

Intervention type: DEVICE
Intervention: Measure the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg), and microperimetry (OPKO Instruments)
Description: Measure the thickness of the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg)and perform central microperimetry using new OPKO Instruments OCT.
Study: NCT02278848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)
Description: Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)
Study: NCT02773017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine A
Description: initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine B
Description: initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine C
Description: initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
Study: NCT02372019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBM With Active Fear Reactivation
Description: Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 10 minutes afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. This training takes places during the memory reconsolidation window that opens after fear reactivation, during which time the fear memory is in a labile state and thus more amenable to rewriting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBM With Inert Fear Reactivation
Description: Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. Because this training takes places well outside of the memory reconsolidation window that opens shortly after fear reactivation, the reactivation is not expected to have any effect, and only serves as a control.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Inert CBM With Inert Fear Reactivation
Description: Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given an inert form of CBM, which should not influence the direction of interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving neutrally, 7 resolving positively, and 7 resolving negatively. Because the CBM training takes places well outside of the memory reconsolidation window that opens after fear reactivation, the reactivation is not expected to have any effect, and the inert CBM training is not expected to have any effect either. This condition only serves as a control for the other two conditions.